Corneal Versus Conjunctival Delivery Using a Delivery Device

This study has been withdrawn prior to enrollment.

Sponsor:

Information provided by:

Pfizer

ClinicalTrials.gov Identifier:

NCT00143429

First received: September 1, 2005

Last updated: March 1, 2007

Last verified: October 2006

History of Changes

Tracking Information

First Received Date ^ICMJE

September 1, 2005

Last Updated Date

March 1, 2007

Start Date ^ICMJE

Not Provided

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

IOP level in the study eye

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00143429 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Change in ocular safety assessments. Ocular and systemic adverse events throughout the study period

Original Secondary Outcome Measures ^ICMJE

Change in ocular safety assessments.
Ocular and systemic adverse events throughout the study period

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Corneal Versus Conjunctival Delivery Using a Delivery Device

Official Title ^ICMJE

Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device

Brief Summary

Compare the antihypertensive efficacy of three methods for installing Xalatan

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Phase 2

Study Design ^ICMJE

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Treatment

Condition ^ICMJE

Glaucoma, Open-Angle
Ocular Hypertension

Intervention ^ICMJE

Drug: Xalatan

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Withdrawn

Enrollment ^ICMJE

Completion Date

Not Provided

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

Exclusion Criteria:

History of closed/barely open anterior chamber angle or a history of angle closure

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Not Provided

Administrative Information

NCT Number ^ICMJE

NCT00143429

Other Study ID Numbers ^ICMJE

A6111127

Has Data Monitoring Committee

Not Provided

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Pfizer

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Study Director:

Pfizer CT.gov Call Center

Pfizer

Information Provided By

Pfizer

Verification Date

October 2006

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top